I'm Prameela Balakkala, a finance professional and algorithmic strategy developer based in Mangalore, Karnataka, trained at Oracle and the National Institute of Securities Markets. With 10+ years in the financial markets, I specialize in equity, index, options and commodity trading, backed by technical and fundamental ... Read more
Trade Ideas
236
Opinions
644
Followers
111k
Expertise
Quantitative
Growth
Technical
Index Strategies
Market Commentary
Futures & Options
Technical Analysis
Trade Facts
Total Trades
0
Missed Trades
0
Profit Trades
0
0%
Accuracy
Ask me Anything
Got a question? Ask me and I will answer it. Stay curious, stay hungry!
Posts
shared an insight ⚡️ 38 mins ago
Glenmark Pharma Launches Inlyta Generic in the US
GLENMARK Glenmark Pharmaceuticals has launched the authorized generic version of Inlyta (Axitinib) tablets in 1 mg and 5 mg strengths in the United States.
Key Business Highlights
- Product: Axitinib tablets (authorized generic of Inlyta).
- Strengths: 1 mg and 5 mg.
- Market: United States.
- Annual US Market Sales: Approximately $538.4 million.
- Therapeutic Segment: Oncology.
- The launch expands Glenmark's presence in the US specialty generics market.
Business Significance
- Provides an opportunity to participate in a sizeable oncology drug market.
- Strengthens Glenmark's US product portfolio.
- Could support incremental revenue growth, depending on market share and pricing.
Risk Factors
- Competition from other generic manufacturers.
- Pricing pressure in the US pharmaceutical market.
- Market share and prescription uptake may differ from expectations.
- Regulatory and supply-chain requirements.
Market Takeaway
The launch is a positive product development for Glenmark, providing access to a US market with reported annual sales of $538.4 million. Actual revenue contribution will depend on market penetration, competition and pricing.
Disclaimer: For educational purposes only. Not investment advice or a recommendation to buy or sell any security.
9
8
shared an insight ⚡️ 13th Nov
MSPL Shifts to Profit in Q2 FY27 with 19% Revenue Growth
MSPL MSPL has marked a robust recovery in Q2 FY27, turning a net loss into a healthy profit, driven by strong revenue gains and a sharp rise in EBITDA.
📊 Key Financial Highlights – Q2 FY27
✅ Revenue climbed to ₹807 Cr from ₹677 Cr, up 19.2% YoY
✅ Net Profit swung to ₹34.37 Cr from a ₹74.76 Cr loss last year
✅ EBITDA surged 214.5% YoY to ₹71.64 Cr
✅ EBITDA Margin expanded by 5.52 percentage points to 8.88%
🔍 Business Insights
📈 Revenue growth signals better market traction and operational momentum
📈 EBITDA more than tripled, highlighting significant cost control and efficiency gains
📈 Margin improvement underscores stronger profitability and business health
🚦 Risk Considerations
⚡ Sustainability of this turnaround remains a key watchpoint
⚡ Volatility in raw material costs and operating expenses could impact margins
⚡ Demand fluctuations and execution challenges pose ongoing risks
📌 Market Takeaway
MSPL’s Q2 performance showcases a meaningful rebound with improved earnings and margins. While this sets a positive tone, investors should keep an eye on the consistency of these results in future quarters.
Disclaimer: For educational purposes only. Not investment advice or a recommendation to buy or sell any security.
1007
79
shared an insight ⚡️ 13th Nov
GAIL Explores Gas-Based Fertilizer Venture in Andhra Pradesh
GAIL GAIL (India) and KRIBHCO have entered into a Memorandum of Understanding (MoU) with the Andhra Pradesh Economic Development Board to evaluate a gas-based fertilizer manufacturing project in the state.
📌 Key Highlights
✅ Partnership: GAIL (India) & Krishak Bharati Cooperative Limited (KRIBHCO)
✅ Government Collaboration: Andhra Pradesh Economic Development Board
✅ Project Focus: Gas-based fertilizer plant
✅ Location: Andhra Pradesh
✅ Status: MoU signed for initial exploration
🔍 Business Implications
📈 Potential to open new growth avenues for GAIL in fertilizer production and natural gas infrastructure
📈 Expected rise in industrial natural gas demand linked to the plant
📈 Supports domestic fertilizer manufacturing, bolstering India’s agricultural sector
📈 Could secure long-term gas supply contracts for GAIL if the project advances
🚦 Risks to Consider
⚡ Project feasibility and capital investment remain uncertain
⚡ Natural gas availability and pricing could impact viability
⚡ Challenges around land acquisition and infrastructure development
⚡ MoU signals intent but does not guarantee project execution
Expert watch: This MoU marks a strategic opportunity for GAIL to diversify and strengthen its footprint in agrochemicals and energy sectors. However, investors should track progress on feasibility studies, investment decisions, and regulatory approvals closely.
Disclaimer: For educational purposes only. Not investment advice or a recommendation to buy or sell any security.
What are the top stock recommendations by Prameela Balakkala?
Prameela Balakkala regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include GLENMARK, MSPL and GAIL. Explore Prameela Balakkala's complete list of posts and trade views on their StockGro profile.
How can I follow Prameela Balakkala's latest investment insights?
You can follow Prameela Balakkala's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.
What is Prameela Balakkala's investment strategy?
Prameela Balakkala follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.
How long has Prameela Balakkala been a SEBI-registered Research Analyst (RA)?
Prameela Balakkala has been a SEBI-registered Research Analyst and have 10+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.
Where can I see Prameela Balakkala's past performance and stock picks?
You can check Prameela Balakkala's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.
How can I contact Prameela Balakkala for stock market advice?
For stock market guidance from Prameela Balakkala, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.
What is Prameela Balakkala's track record in predicting market movements?
Prameela Balakkala has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.
What is the SEBI Registration number for Prameela Balakkala?
Prameela Balakkala is a SEBI-registered Research Analyst with the SEBI Registration INH000016074. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.